Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

CNW Group11-12

A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product HERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /CNW/ -- Innocan Pharma Corporation (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482630997?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50","is_english":true,"pubTime":"2024-11-12 05:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482630997","market":"us","top_or_hot":-1,"title":"Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand","media":"CNW Group","content":"<div>\n<p>A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product\nHERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /CNW/ -- Innocan Pharma Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/innocan-direct-full-focus-following-210100841.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 05:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/innocan-direct-full-focus-following-210100841.html><strong>CNW Group</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product\nHERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /CNW/ -- Innocan Pharma Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/innocan-direct-full-focus-following-210100841.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/innocan-direct-full-focus-following-210100841.html","article_id":"2482630997","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482630997","pubTimestamp":1731358860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product. Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505 abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan's non-clinical development plan and Phase I clinical study design for the LPT-CBD's Investigational New Drug  filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA's Center for Veterinary Medicine  with the issuance of an Investigational New Animal Drug  designation in July.Following the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD pro","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4181":"酒店及度假村房地产投资信托","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","ACB":"奥罗拉大麻公司","BK4532":"文艺复兴科技持仓","BK4504":"桥水持仓","BK4218":"酒店及度假村房地产信托","BK4557":"大麻股","BK4139":"生物科技","BK4018":"居家用品","CVM":"CEL-SCI Corp","BK4567":"ESG概念","CLX":"高乐氏","BK4585":"ETF&股票定投概念","INNPF":"Innocan Pharma Corp.","INN":"Summit Hotel Properties","BK4588":"碎股","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Innocan将全力关注FDA的积极参与和巨大的潜在市场需求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INNPF":1,"CVM":1,"CLX":1,"INN":0.9,"ACB":0.9},"content_text":"A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product\nHERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (\"Innocan\" or the \"Company\"), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA).\n\n\n\nInnocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan's non-clinical development plan and Phase I clinical study design for the LPT-CBD's Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA's Center for Veterinary Medicine (CVM) with the issuance of an Investigational New Animal Drug (INAD) designation in July.\nGiven recent U.S. Pet industry reports and data released by the American Pet Products Association (APPA) and the National Pet Owners Survey*, Innocan recognizes significant market potential for an injectable treatment for chronic pain in animals:\n\n66% of U.S. households – 87 million homes – own one or more pets, including 58 million with dogs and 40 million with cats.\nIn 2024, U.S. pet industry expenditures are projected to reach US $156 billion, up from USD $147 billion in 2023, with USD $39 billion anticipated for pharmaceutical drugs and veterinary care.\n\nThis new data represents a significantly large and growing market for effective veterinary health products like LPT-CBD, Innocan's monthly injectable drug product. Innocan's unique technology is comprised of liposomes loaded with CBD for the treatment of chronic pain. LPT-CBD has demonstrated promising results in multiple animal model tests, as previously reported, providing extended pharmacokinetic benefits and effective pain relief lasting up to four weeks.\nFollowing the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD project, thereby sunsetting its Cannabinoid-Loaded Exosome (CLX) project conducted with Ramot of Tel Aviv University (Ramot) under Prof. Daniel Offen. A suitable notice of termination of its sponsored research agreement dated April 17, 2020 and its research and funding agreement with Ramot dated December 6, 2021 has been sent, concluding this collaboration.\n\"The latest pet industry reports show that the market potential of the LPT-CBD products in veterinary health is clearly significant,\" commented Iris Bincovich, CEO of Innocan. \"Our commitment to pioneering solutions for chronic pain in animals aligns with the growing need for effective, compassionate care. By dedicating increased resources to this market, we can expedite our path to market for LPT-CBD and meet the demands of a dynamic and expanding pet care industry.\"\n* https://www.marketwatch.com/guides/pet-insurance/pet-ownership-statistics/\nAbout Innocan Pharma:\nInnocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.\nFor more information: www.innocanpharma.com\nContact Information:For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@innocanpharma.com\nNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.\nCaution Regarding Forward-Looking Information\nCertain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.\nForward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.\nReaders are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.\nLogo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg\n View original content:https://www.prnewswire.com/news-releases/innocan-to-direct-full-focus-on-following-positive-fda-engagement-and-significant-potential-market-demand-302301258.html\nSOURCE Innocan Pharma Corporation\n View original content: http://www.newswire.ca/en/releases/archive/November2024/11/c5249.html","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482630997"}